Harnessing the regenerative power of the human body to develop transformative medicines for CNS disorders
Our mission is to improve life health for people affected by CNS disorders by driving the regenerative power of the human body. Altering the progressive and debilitating course of these conditions by returning the brain to a healthier state will transcend the benefits offered by existing therapies and allow people to live the futures they deserve.
CNS drug development has long suffered from limited innovation and high failure rates, especially for drugs that strive to modify the underlying cause of disease. Developing successful therapies requires several factors, including a deep knowledge of underlying disease mechanisms, exceptional chemistry, insights into viable translational models and strategies to match the right patients to the most effective drugs. We have brought these elements together at Autobahn to make a real difference in the lives of people.
Leadership TeamAnne M. Danks, Ph.D.Vice President, Preclinical Development
Board of DirectorsScott GiacobelloChief Financial Officer, GW Pharmaceuticals plc
Scientific AdvisorsS. Ali Fatemi, M.D., M.B.A.Chief Medical Officer at Kennedy Krieger Institute and Professor of Neurology and Pediatrics at John Hopkins University
Our ScienceOur Science